Arrowhead Pharmaceuticals (ARWR) Other Non-Current Liabilities (2011 - 2026)
Arrowhead Pharmaceuticals (ARWR) posted Other Non-Current Liabilities of $383.8 million for Q1 2026, up 2.36% on a QoQ basis from $375.0 million in Q4 2025, and up 8.96% year-over-year from $352.3 million in Q1 2025.
Arrowhead Pharmaceuticals (ARWR) Other Non-Current Liabilities (2011 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals' Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $383.8 million for Q1 2026.
- Quarterly Other Non-Current Liabilities rose 8.96% year-over-year to $383.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $383.8 million (up 8.96% YoY) and the FY2025 annual result came in at $367.4 million, up 7.63% from the prior year.
- Other Non-Current Liabilities was $383.8 million for Q1 2026 at Arrowhead Pharmaceuticals, up from $375.0 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $383.8 million in Q1 2026 and bottomed at $669000.0 in Q2 2023.
- A 5-year average of $299.8 million and a median of $338.7 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities soared 50128.85% — and 2025, when it gained 7.21%.
- Arrowhead Pharmaceuticals' Other Non-Current Liabilities stood at $252.8 million in 2022, then climbed by 8.24% to $273.7 million in 2023, then advanced by 26.7% to $346.8 million in 2024, then gained by 8.14% to $375.0 million in 2025, then increased by 2.36% to $383.8 million in 2026.
- Business Quant data shows ARWR's Other Non-Current Liabilities at $383.8 million in Q1 2026, $375.0 million in Q4 2025, and $367.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Arrowhead Pharmaceuticals | 11.98 Bn | 10.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 383.83 Mn |
| Dec 31, 2025 | 375.00 Mn |
| Sep 30, 2025 | 367.40 Mn |
| Jun 30, 2025 | 360.25 Mn |
| Mar 31, 2025 | 352.28 Mn |
| Dec 31, 2024 | 346.78 Mn |
| Sep 30, 2024 | 341.36 Mn |
| Jun 30, 2024 | 336.03 Mn |
| Mar 31, 2024 | 280.94 Mn |
| Dec 31, 2023 | 273.69 Mn |
| Sep 30, 2023 | 268.33 Mn |
| Jun 30, 2023 | 669,000.00 |
| Mar 31, 2023 | 257.91 Mn |
| Dec 31, 2022 | 252.85 Mn |
| Sep 30, 2018 | 200,000.00 |
| Jun 30, 2018 | 200,000.00 |
| Mar 31, 2018 | 200,000.00 |
| Dec 31, 2017 | 200,000.00 |
| Sep 30, 2017 | 200,000.00 |
| Jun 30, 2017 | 200,000.00 |